Literature DB >> 1633074

Prophylactic nitrate therapy in angina pectoris--is there an optimal treatment regimen?

G Olsson1, J Allgén.   

Abstract

1. Nitrates have a place in the prophylactic treatment of patients with angina pectoris. Their efficacy is not in doubt. 2. However, there may be some practical problems associated with their use, such as unreliable absorption, short duration of action, treatment-induced headache, development of nitrate tolerance and a suggested rebound phenomenon observed during intermittent dosing. Furthermore, patient convenience with treatment schedule and patient compliance have to be considered during prophylactic treatment. The present article discusses how many of these problems may be solved by selection of formulation as well as nitrate compound. 3. The development of controlled-release formulations producing sufficiently high nitrate plasma concentration during part of the day followed by nitrate-poor rather than nitrate-free interval, have the potential to prevent both nitrate tolerance and rebound phenomenon, and produce a sufficiently long duration of action with a convenient once daily regimen.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1633074      PMCID: PMC1381218          DOI: 10.1111/j.1365-2125.1992.tb04144.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

Review 1.  Pharmacokinetics of various preparations of organic nitrates.

Authors:  J P Kampmann
Journal:  Drugs       Date:  1987       Impact factor: 9.546

2.  Sustained effect of and lack of development of tolerance to controlled-release isosorbide-5-mononitrate in chronic stable angina pectoris.

Authors:  G Wisenberg; C Roks; P Nichol; M D Goddard
Journal:  Am J Cardiol       Date:  1989-09-15       Impact factor: 2.778

3.  Intermittent transdermal nitroglycerin monotherapy in stable exercise-induced angina: a comparison with a continuous schedule.

Authors:  M Ferratini; S Pirelli; P Merlini; P Silva; G Pollavini
Journal:  Eur Heart J       Date:  1989-11       Impact factor: 29.983

4.  Experience of long term treatment and different dosage regimens of isosorbide 5-mononitrate.

Authors:  M Meffert; I M Paeckelmann
Journal:  Drugs       Date:  1987       Impact factor: 9.546

5.  The effect of isosorbide-5-mononitrate (5-ISMN) Durules on exercise tolerance in patients with exertional angina pectoris. A placebo controlled study.

Authors:  G Nyberg; P Carlens; E Lindström; T Lundman; R Nordlander; N Rehnqvist; G Ulvenstam; A Aberg; H Aström
Journal:  Eur Heart J       Date:  1986-10       Impact factor: 29.983

6.  Long term efficacy of a controlled-release formulation of isosorbide 5-mononitrate (Imdur) in angina patients receiving beta-blockers.

Authors:  A Uusitalo
Journal:  Drugs       Date:  1987       Impact factor: 9.546

7.  Abrupt withdrawal of isosorbide-5-mononitrate in Durules (Imdur) after long term treatment in patients with stable angina pectoris.

Authors:  N Rehnqvist; G Olsson; J Engvall; U Rosenqvist; G Nyberg; A Aberg; G Ulvenstam; A Uusitalo; O Keyriläinen; P Reinikainen
Journal:  Eur Heart J       Date:  1988-12       Impact factor: 29.983

8.  Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina.

Authors:  H DeMots; S P Glasser
Journal:  J Am Coll Cardiol       Date:  1989-03-15       Impact factor: 24.094

9.  Oral isosorbide dinitrate in angina pectoris: comparison of duration of action an dose-response relation during acute and sustained therapy.

Authors:  U Thadani; H L Fung; A C Darke; J O Parker
Journal:  Am J Cardiol       Date:  1982-02-01       Impact factor: 2.778

10.  Anti-anginal efficacy of a controlled-release formulation of isosorbide-5-mononitrate once daily in angina patients on chronic beta-blockade.

Authors:  A Uusitalo; O Keyriläinen; R Härkönen; P Rautio; N Rehnqvist; J Engvall; U Rosenqvist; G Nyberg; A Aberg; G Ulvenstam
Journal:  Acta Med Scand       Date:  1988
View more
  1 in total

Review 1.  Novel oral drug formulations. Their potential in modulating adverse effects.

Authors:  A T Florence; P U Jani
Journal:  Drug Saf       Date:  1994-03       Impact factor: 5.606

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.